• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form RW filed by Palisade Bio Inc.

    6/11/25 9:50:44 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PALI alert in real time by email
    RW 1 formrw.htm RW

     

    Palisade Bio, Inc.

    7750 El Camino Real, Suite 2A

    Carlsbad, CA 92009

     

    June 11, 2025

    VIA EDGAR

     

    U.S. Securities and Exchange Commission

    Division of Corporation Finance

    Office of Life Sciences

    100 F Street, N.E.

    Washington, D.C. 20549

     

    Re:

    Palisade Bio, Inc.

    Withdrawal of Registration Statement on Form S-1

    File No. 333-287578

     

    Ladies and Gentlemen:

     

    Palisade Bio, Inc. (the “Company”) hereby requests, pursuant to Rule 477 under the Securities Act of 1933, as amended (the “Securities Act”), that the U.S. Securities and Exchange Commission (the “SEC”) consent to the withdrawal of the Company’s Registration Statement on Form S-1 (File No. 333-287578), initially filed with the SEC on May 27, 2025, together with all exhibits and amendments thereto (collectively, the “Registration Statement”), as of the date hereof or at the earliest practicable date hereafter.

     

    The Company is seeking withdrawal of the Registration Statement at this time because the Company has determined that it is not in the best interests of the Company to conduct the proposed offering at this time. The Registration Statement has not been declared effective and no securities covered by the Registration Statement have been issued or sold. Based on the foregoing, the Company submits that the withdrawal of the Registration Statement is consistent with the public interest and protection of investors as contemplated by Rule 477(a). The Company requests that, in accordance with Rule 457(p) under the Securities Act, all fees paid to the SEC in connection with the filing of the Registration Statement be credited for future use.

     

    We respectfully request that the SEC provide a copy of any order consenting to the withdrawal of the Registration Statement to Jeffrey C. Thacker of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, via email at [email protected].

     

    If you have any further questions regarding this request for withdrawal, or if you require any additional information, please contact our attorney, Jeffrey C. Thacker of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, at (858) 436-8064. Thank you for your assistance.

     

     

     

     

    Very truly yours,  
         
    Palisade Bio, Inc.  
         
    By: /s/ JD Finley  
      JD Finley  
      Chief Executive Officer  

     

    cc:

    Jeffrey C. Thacker, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP

    Ryan J. Gunderson, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP

    John E. Maciejewski, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP

     

     

     

     

     

    Get the next $PALI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PALI

    DatePrice TargetRatingAnalyst
    2/2/2022$5.00Buy
    Ladenburg Thalmann
    8/31/2021$7.00Buy
    Maxim Group
    More analyst ratings

    $PALI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Williams Donald Allen bought $4,863 worth of Comon Stock (1,000 units at $4.86) (SEC Form 4)

      4 - PALISADE BIO, INC. (0001357459) (Issuer)

      5/29/24 3:47:14 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Finley John David bought $4,810 worth of shares (1,000 units at $4.81), increasing direct ownership by 13% to 8,437 units (SEC Form 4)

      4 - PALISADE BIO, INC. (0001357459) (Issuer)

      5/28/24 6:02:01 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Finley John David bought $4,692 worth of shares (10,000 units at $0.47), increasing direct ownership by 13% to 84,649 units (SEC Form 4)

      4 - PALISADE BIO, INC. (0001357459) (Issuer)

      2/7/24 8:30:10 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PALI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn's Disease and Ulcerative Colitis

      Study met its primary endpoints of safety, tolerability, and pharmacokinetics (PK)  No serious adverse events (SAEs) or treatment-emergent adverse events (TEAEs) related to laboratory values or EKGs observed across SAD/MAD cohorts Management releases a "What This Means" segment discussing the topline Phase 1a data; Access here Carlsbad, CA, May 27, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced positive topline results from its completed Phase

      5/27/25 8:30:00 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases

      Two posters presented at Digestive Disease Week (DDW) 2025 Preclinical results indicate that PALI-2108 effectively modulates inflammatory pathways in the colon, promoting a favorable immune response Company advancing Phase 1a/b study of PALI-2108 and has demonstrated a favorable safety profile in single-ascending-dose cohorts Carlsbad, CA, May 06, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the presentation of positive preclinical data from

      5/6/25 8:30:00 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Palisade Bio's AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit

      Carlsbad, CA, May 01, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it has been selected to give an oral presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit being held May 13–15, 2025 in Boston, MA. Details of the oral presentation are as follows: Session: Advancing AI-Driven Diagnostics & Enhancing Patient Monitoring to Personalize Treatment Decisions & Improve Long-Term Patient OutcomesTitle: Improving

      5/1/25 8:30:00 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care